Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study
View Full Paper
Ask AI
Bookmark
Share
Key result
Sitagliptin significantly attenuated the 24-month increase in the echocardiographic parameter of diastolic dysfunction (E/e') compared to conventional treatment (-0.18 vs 1.91, p=0.008).
Why the study?
Does sitagliptin improve echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes?
Population
115 adults older than 30 years with type 2 diabetes, mean age 69, 67% male, Japan-based. Key exclusion…
Comparison
Sitagliptin added to conventional antidiabetic… vs Conventional glucose-lowering treatment for 24…
Design
RCT, 1:1 ratio, open-label, blinded-endpoint trial
Follow-up
24 months
Authors
Discussion
Loading...
Member takes
Implication
May attenuate diastolic dysfunction progression in T2D; hypothesis-generating and requires RCTs before practice change.
Study Design
Type
RCT (n=115)
Blinding
Open-label, blinded-endpoint
Randomization
1:1
Multicenter
Yes
Structured PICO
Does sitagliptin improve echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes?
P
Population
115 patients over 30 years of age with type 2 diabetes on conventional treatment, free of severe heart failure, followed for 24 months.
I
Intervention
Sitagliptin added to conventional antidiabetic treatment for 24 months
C
Comparator
Conventional glucose-lowering treatment (diet, exercise, and/or oral antidiabetic agents except incretin-related therapy) for 24 months
O
Outcome
Comparison of the changes in the ratio of peak early diastolic transmitral flow velocity (E) to peak early diastolic mitral annular velocity (e') (E/e') between the two groups from baseline to 24 monthssurrogate
Main Result
Absolute Event Rate: -0.18% vs 1.91%
p-value: p=0.008
Limitations
- Small sample size due to echocardiography being an optional examination
- Potential selection bias as echocardiography was left to the judgment of each researcher
- Included only Japanese subjects
- Excluded patients with severe heart failure (NYHA III and IV), limiting generalizability to patients with overt heart failure
Cite This Study
Yamada et al. (2017) conducted an RCT in Type 2 diabetes (n=115). Sitagliptin vs. Conventional antidiabetic treatment was evaluated on Baseline-adjusted change in E/e' (ratio of peak early diastolic transmitral flow velocity to peak early diastolic mitral annular velocity) at 24 months (p=0.008). Sitagliptin significantly attenuated the 24-month increase in the echocardiographic parameter of diastolic dysfunction (E/e') compared to conventional treatment (-0.18 vs 1.91, p=0.008).
View Full Paper
Ask AI
Bookmark
Share